Markets:

Overview

News

Currencies

International

Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

8.170 +0.350 (+4.48%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Billionaire Andreas Halvorsen Just Bought DNA Stock. Here’s Why. ↗

July 07, 2022

DNA stock is surging higher today following large purchases from Viking Global's Andreas Halvorsen and Ark Invest's Cathie Wood.

Via InvestorPlace

Beware These 7 Penny Stock Bubbles Getting Ready to Burst ↗

July 06, 2022

The following penny stocks have built up a large bubble that is yet to burst. They are likely to burst soon due to the market decline.

Via InvestorPlace

Is TSLA Stock Still a Buy? 5 Analysts Weigh In. ↗

July 05, 2022

Tesla (TSLA) stock is a hot topic on Tuesday as analysts react to the company's EV deliveries for the second quarter of 2022.

Via InvestorPlace

Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock ↗

July 05, 2022

Cathie Wood's Ark Invest has purchased more than 3.5 million shares of DNA stock since June 29, its first purchases in over a month.

Via InvestorPlace

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group ↗

June 23, 2022

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity...

Via Benzinga

Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock ↗

May 20, 2022

Shares of DNA stock are in focus following Ark Invest's buying spree this month. In the past two days, Ark has purchased 4.5 million shares.

Via InvestorPlace

Losing Money Is in Ginkgo Bioworks Holdings’ DNA ↗

May 19, 2022

DNA stock is a falling knife in 2022, and the latest earnings do not justify being optimistic about reaching profitability soon.

Via InvestorPlace

Why Ginkgo Bioworks Stock Is Falling After Hours ↗

May 16, 2022

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company

Via Benzinga

Cronos Group And Ginkgo Bioworks Achieve Rare Cannabinoid THCV Equity Milestone ↗

June 21, 2022

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) and Ginkgo Bioworks (NYSE: DNA) achieved the third target productivity milestone in their partnership

Via Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗

June 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Cathie Wood Is Selling Gene Editing Stocks. Here’s Why. ↗

June 02, 2022

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Via InvestorPlace

ADSK Stock Sinks 8% Following Analyst Downgrade ↗

May 23, 2022

Autodesk (ADSK) stock is slipping on Monday after getting hit with a downgrade and price target drop from Deutsche Bank analyst Bhavin Shah.

Via InvestorPlace

Benzinga Bulls And Bears Of The Week: Netflix, Coinbase, Apple, Rivian And A Biotech Scooped Up By Cathie Wood ↗

May 21, 2022

Benzinga has examined the prospects for many investor favorite stocks over the past week, while offering a 24/7 news feed, live chat and charting software on Benzinga Pro.

Via Benzinga

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Why Is Ginkgo Bioworks (DNA) Stock Up Today? ↗

April 13, 2022

Biotechnology company Ginkgo Bioworks has a host of promising collaboration announcements. DNA stock is up as a result.

Via InvestorPlace

74 Biggest Movers From Yesterday ↗

June 03, 2022

Gainers

Via Benzinga

Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock ↗

May 19, 2022

Ark Investment Management, led by Tesla Inc.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022 ↗

May 18, 2022

Via Benzinga

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half ↗

May 18, 2022

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Down Over 1%; Jumia Technologies Shares Spike Higher ↗

May 17, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday.

Via Benzinga

Looking Into Ginkgo Bioworks Holdings's Recent Short Interest ↗

May 13, 2022

Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short,...

Via Benzinga

7 Growth Stocks to Buy on the Dip ↗

May 10, 2022

Although the wave of red ink in the major indices is intimidating, it also presents an intriguing opportunity for growth stocks to buy.

Via InvestorPlace

Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock. Here’s Why. ↗

April 27, 2022

DNA stock is in the spotlight after Ark Invest reported purchasing more than 1.5 million shares this week. So, who else is betting big on Ginkgo?

Via InvestorPlace

7 Biggest Loser Stocks That Could Become Surprising Buys ↗

April 27, 2022

A huge pouring of red ink can sometimes lead to extraordinary gains, though you’ve got to be aware of the risks.

Via InvestorPlace

28 Biggest Movers From Yesterday ↗

April 14, 2022

Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on...

Via Benzinga

NYSE:DNA Long Term Investor Alert: Investigation of Potential Wrongdoing at Ginkgo Bioworks Holdings, Inc. ↗

April 13, 2022

San Diego, CA -- (SBWIRE) -- 04/13/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ginkgo Bioworks Holdings, Inc.

Via SBWire

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm ↗

April 11, 2022

Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company....

Via Benzinga

Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here’s Why. ↗

April 07, 2022

Baillie Gifford recently disclosed that it purchased 48.8 million shares of DNA stock on March 31. The firm has a $180 billion portfolio.

Via InvestorPlace

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

April 05, 2022

From Twist Bioscience Corporation

Via Business Wire

53 Biggest Movers From Yesterday ↗

March 30, 2022

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Starting at $3.75/week.

Subscribe Today